ACE1831 Trial
Phase 1
42
about 4.7 years
18+
5 sites in FL, GA, IN +2
What this study is about
Researchers are testing a new treatment called ACE1831 for people with relapsed or refractory CD20-expressing B-cell malignancies. The trial will evaluate the safety, tolerability, and effectiveness of ACE1831 in adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ACE1831
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, obinutuzumab
infusion, injection, intravenous
Primary: Change from baseline clinical laboratory tests results, Change from baseline in ECOG status, Change from baseline in electrocardiogram (ECG) results, Change from baseline in physical examination results, Change from baseline in urinalysis results, Change from baseline in vital signs results, Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs), Maximum Tolerated Dose (MTD)
Secondary: Objective Response Rate (ORR)
Oncology